Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.

Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.

Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR expression and methods of using these splice-switching oligonucleotides to treat cancer, specifically castrate resistant prostate cancer.

Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR expression and methods of using these splice-switching oligonucleotides to treat cancer, specifically castrate resistant prostate cancer.

Abstract: In some examples, a smart assistant device may receive information associated with a previous medical treatment provided to a patient by one or more medical devices. The smart assistant device may determine, based at least in part on the received information and a medical treatment plan for the patient, an adjustment to one or more parameters of an upcoming scheduled medical treatment provided by the one or more medical devices. The smart assistant device may program or otherwise control the one or more medical devices to make the adjustment to the one or more parameters of the upcoming scheduled medical treatment provided by the one or more medical devices.

Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.

Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.

Abstract: The present disclosure provides biomarkers for the identification of prostate cancer and methods of use. The present disclosure also provide biomarkers that can be used for determining risk of developing prostate cancer, aggressiveness of prostate cancer and survival rate for subpopulations of African American males or non-Hispanic white males.

Abstract: The present disclosure provides prochelators as targeted prodrugs for cancer, such as prostate cancer, and methods of making and using the same.

Abstract: The present disclosure provides biomarkers for the identification of prostate cancer and methods of use. The present disclosure also provide biomarkers that can be used for determining risk of developing prostate cancer, aggressiveness of prostate cancer and survival rate for subpopulations of African American males or non-Hispanic white males.

Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR expression and methods of using these splice-switching oligonucleotides to treat cancer, specifically castrate resistant prostate cancer.

Abstract: A system to optically measure an ear includes a controller with logic that when executed by the controller causes the system to perform operations. Operations may include capturing the one or more images of the ear using the one or more image sensors, and generating image data from the one or more images. 3D keypoints of the ear are calculated from the image data, and a 3D model of the ear is generated using the 3D keypoints.

Abstract: A system to optically measure an ear includes a controller with logic that when executed by the controller causes the system to perform operations. Operations may include capturing the one or more images of the ear using the one or more image sensors, and generating image data from the one or more images. 3D keypoints of the ear are calculated from the image data, and a 3D model of the ear is generated using the 3D keypoints.

Abstract: The present disclosure provides prochelators as targeted prodrugs for cancer, such as prostate cancer, and methods of making and using the same.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for determining atmospheric conditions. In one aspect, a method includes receiving data relating to atmospheric conditions collected at a particular altitude located within the stratosphere, providing the data to a machine-learned model that has been trained using a training data set collected in a controlled environment, determining, by the machine-learned model, atmospheric conditions data for the particular altitude based on the data collected for the particular altitude and storing the atmospheric conditions data for the particular altitude.

Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.

Abstract: The present disclosure provides biomarkers for the identification of prostate cancer and methods of use. The present disclosure also provide biomarkers that can be used for determining risk of developing prostate cancer, aggressiveness of prostate cancer and survival rate for subpopulations of African American males or non-Hispanic white males.

Abstract: Provided are methods for detecting circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.

Abstract: An estimation method includes identifying a timing factor for a print job. The timing factor is then used to estimate a composition time for the print job.